Microsoft is extending Dataverse into coding-agent marketplaces while expanding its MCP tools, certification program and governance controls.

Ongava has appointed businessman and former Brave Warriors captain Amos Shiyuka as the Ongava Game Reserve and Ongava Hai//om Tourism board chairperson.

Amy Perrotta, the founder of a career branding company, says an effective résumé makes a recruiter "want to pick up the phone ...

CATL, the world’s largest battery manufacturer, is accelerating the shift toward sodium-ion technology. With lower-cost materials, improved safety, and performance that is rapidly closing the gap with ...

Citroën is bringing back the 2CV as a new small electric car, confirming the plans revealed exclusively by The Independent earlier this year. In January, Citroën CEO Xavier Chardon told us that the ...

SINGAPORE, May 20 (Reuters) - Singapore's banks and financial firms should use artificial intelligence to create better jobs and train workers for higher-value roles, not just cut costs, Deputy Prime ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Apple AAPL0.70%increase; up pointing triangle, long revered for its premium-priced products, has managed to develop a booming business selling cheaper devices when most gadget makers are being ...

Markdown has emerged as the lingua franca of AI, especially with the proliferation of AI agents. But an Anthropic engineer argues that HTML is a better choice for output. And despite my love of ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Artificial intelligence isn't just helping candidates write resumes or ...

Trials of the British Army’s Ajax armoured vehicles are set to resume, despite major delays amid concern for soldiers’ safety. Minister for Defence Readiness and Industry Luke Pollard announced in ...

VESALIUS-CV shows that evolocumab delivers a 31% relative risk reduction in major cardiovascular events in high-risk diabetic patients without established atherosclerosis—making a compelling case for ...